Champions Oncology Inc CSBR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
-
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024
-
Champions Oncology Reports Quarterly Revenue of $14.0 Million
-
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
Trading Information
- Previous Close Price
- $4.85
- Day Range
- $4.75–5.04
- 52-Week Range
- $3.60–7.13
- Bid/Ask
- $4.76 / $5.26
- Market Cap
- $65.39 Mil
- Volume/Avg
- 53,815 / 48,380
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.28
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.05%
Company Profile
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 306
Comparables
Valuation
|
Metric
|
CSBR
|
ACLX
|
ARTV
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 9.26 | — |
Price/Sales | 1.28 | 29.60 | 3.70 |
Price/Cash Flow | 55.65 | 545.39 | — |
Price/Earnings
CSBR
ACLX
ARTV
Financial Strength
|
Metric
|
CSBR
|
ACLX
|
ARTV
|
|---|---|---|---|
Quick Ratio | 0.62 | 5.85 | 4.43 |
Current Ratio | 0.69 | 6.01 | 4.59 |
Interest Coverage | — | −28.35 | — |
Quick Ratio
CSBR
ACLX
ARTV
Profitability
|
Metric
|
CSBR
|
ACLX
|
ARTV
|
|---|---|---|---|
Return on Assets (Normalized) | −7.44% | −1.88% | −16.21% |
Return on Equity (Normalized) | — | −3.31% | — |
Return on Invested Capital (Normalized) | −27.82% | −7.10% | — |
Return on Assets
CSBR
ACLX
ARTV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vqbgkkgkz | Nnmq | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gyhppdgg | Hdgzwx | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dvznfhntn | Qhqqbv | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qhdxgqpls | Ckxcp | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Ctqdxdj | Wlzsy | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Hwsdmzjsx | Srb | $28.0 Bil | |||
| Moderna Inc
MRNA
| Wmywvch | Rzttf | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Sppkyfjh | Fmkms | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hkdgnsl | Qqsjfp | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mxpckqxlg | Ncpdqv | $12.6 Bil |
United States